Earnings Previews: AbbVie, AstraZeneca, Chevron, Exxon
Yet another look at some of the more than 900 publicly traded companies scheduled to report March quarter earnings this week. Two U.S. oil behemoths and two pharmaceutical giants are the subjects of this preview.
Looking ahead to companies reporting earnings after Wednesday’s closing bell, we have previewed Apple, Facebook, Ford and Qualcomm. Four more stocks reporting results before markets open Thursday, Altria, Caterpillar, McDonald’s and Merck, were previewed in a second story also posted Tuesday. We also have looked at four companies reporting results after markets close Thursday.
The four companies previewed in this story are scheduled to report earnings before Friday’s opening bell.
Another widely traded pharmaceutical stock, AbbVie Inc. (NYSE: ABBV), owns the patent on Humira, the best-selling drug in the world, with 2020 revenue of around $20 billion. The company has launched two new drugs that it hopes can help offset Humira’s 43% share of AbbVie’s total annual revenue. Humira loses patent protection in 2023. The May 2020 acquisition of Allergan for $63 billion also adds about $15 billion annually in sales.
Brokerage firms are evenly split on AbbVie, with 10 of 20 rating the stock a Buy or Strong Buy and the others assigning a rating of Hold. At a recent trading price of around $111.80, the stock’s upside potential to a consensus price target of $122.17 is 9%. At the high target of $144, the upside potential rises to nearly 30%.
Estimates for the March quarter call for earnings per share (EPS) of $2.83 (up about 17%) on revenue of $12.76 billion, up 48%. For the full fiscal year, analysts are looking for EPS of $12.45, a gain of 18% year over year, and sales of $55.34 billion, up nearly 21%.
AbbVie stock trades at 9.0 times expected 2021 EPS, 8.2 times estimated 2021 earnings and 9.3 times estimated 2023 earnings. The stock’s 52-week range is $79.11 to $113.41, and AbbVie pays an annual dividend of $5.20 (yield of 4.67%).
U.K.-based AstraZeneca PLC (NYSE: AZN) already has said that it will not earn a profit from the vaccine it developed with Cambridge University as long as COVID-19 is treated as a pandemic. The vaccine also has hit a few headwinds due to rare blood clots, manufacturing delays and supply issues. Despite not making a profit on its coronavirus vaccine, the drugmaker said in February it expected 2021 revenue to rise by a low-teens percentage on the strength of its core products for treating diabetes, heart and kidney disease, and cancer.
The stock is lightly covered in the United States, with just five brokerages total, of which four have the stock as a Buy or Strong Buy. The consensus price target on the stock is $63.60, and at a current price of around $52, the implied upside on the shares is 22%. At the high target of $69.40, the upside potential rises to more than 33%.
A single analyst expects AstraZeneca to report EPS of $0.73, an increase of nearly 50% year over year, and revenue of $7.14 billion, up 12.4% year over year. For the full year, EPS is forecast at $2.11, up 5% year over year, and revenue is tabbed to come in at $31.47 billion.
Source: Read Full Article